Condition: Dyslipidemias · Cardiovascular Diseases · HIV Infections · Sponsor: Priscilla Hsue, MD
This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.
This description comes directly from the study's public registry record.
Marta Levkova · 628-206-8037 · marta.levkova@ucsf.edu
Always discuss trial participation with your own doctor first.
| UCLA Center for Clinical AIDS Research and Education (CARE) | Los Angeles, California, United States | Recruiting |
| San Francisco General Hospital | San Francisco, California, United States | Recruiting |
| UT Health Houston | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05488431